News | Heart Valve Technology | November 10, 2015

First Pennsylvania Patient Treated in Next Generation Aortic Heart Valve Study

Trial at PinnacleHealth CardioVascular Institute compares Direct Flow Medical TAVR device to Medtronic CoreValve

SALUS trial, Direct Flow Medical TAVR device, Medtronic CoreValve, PinnacleHealth CardioVascular Institute

Image courtesy of Direct Flow Medical

November 10, 2015 — PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a randomized trial studying a new heart valve to treat aortic valve disorders. Harrisburg Hospital is the only trial site in Pennsylvania. This study represents the next wave of research with aortic valves that conform to the patient's anatomy.

According to an article published in the Journal of the American College of Cardiology, aortic stenosis (AS) is the most common valvular heart disease in developed countries with prevalence estimated between 3 and 23 percent. AS mainly affects older people, due to scarring and calcium buildup in the valve cusp. With a growing elderly population, AS is anticipated to become a major public health concern.

SALUS is a prospective, multicenter clinical trial of the Direct Flow Medical Transcatheter Aortic Valve System, which will enroll 912 subjects in up to 45 sites in the United States. Mubashir Mumtaz, M.D., FACS, FACC, chief of cardiothoracic surgery, and William Bachinsky, M.D., FACC, medical director of vascular services, serve as co-principal investigators locally at PinnacleHealth.

"Our team of cardiologists and cardiovascular surgeons has a long-standing reputation for treating complex heart conditions," said Mumtaz. "We feel it is our mission to continually assess new, innovative options for our patients."

The purpose of SALUS is to compare the Direct Flow Medical system to the commercially available Medtronic CoreValve in high- and extreme-risk patients with severe symptomatic aortic stenosis. The Direct Flow Medical valve has a double-ring, polymer-based frame, while the Medtronic CoreValve is held by a metal frame. The unique design of the investigational device allows the valve to conform to the patient's anatomy. Unlike other transcatheter aortic valve replacement procedures, the investigational valve does not require rapid pacing of the heart through electrical stimulation.

At PinnacleHealth, there is a team approach to transcatheter aortic valve replacement (TAVR) procedures. TAVR procedures, such as those using Direct Flow Medical and CoreValve valves, involve direct care by both a cardiothoracic surgeon and interventional cardiologist in a specially equipped operating room. 

For more information: www.pinnaclehealth.org

Related Content

Boston Scientific Prevails in U.S. Edwards Lifesciences Litigation
Feature | Heart Valve Technology | December 12, 2018
A jury in the U.S. District Court for the District of Delaware determined Dec. 11 that the Boston Scientific U.S....
First TriCinch Coil Tricuspid Repair Systems Implanted in U.S.
News | Heart Valve Technology | November 06, 2018
4Tech Inc. initiated its U.S. Early Feasibility Study of the TriCinich Coil System following U.S. Food and Drug...
Valve Replacement Volume Key to Successful Patient Outcomes
News | Heart Valve Technology | November 02, 2018
Hospitals that routinely perform a heart valve replacement procedure requiring open heart surgery are more likely to...
Prosthetic Valve Mismatches Common in TAVR Procedures
News | Heart Valve Technology | October 03, 2018
A high number of patients in a study who underwent transcatheter aortic valve replacement (TAVR) experienced severe and...
Local Anesthesia Safe and Effective for Intermediate- and High-Risk TAVR Patients
News | Heart Valve Technology | September 28, 2018
The first randomized study to compare general versus local anesthesia during transcatheter aortic valve replacement (...
MitraClip Reduces Mortality for Heart Failure Patients With Secondary Mitral Regurgitation
News | Heart Valve Technology | September 26, 2018
Patients with heart failure and secondary mitral regurgitation (MR) who remained symptomatic despite maximally...
Ancora Heart Announces Positive Interim Analysis of AccuCinch Ventricular Repair System for Heart Failure
News | Heart Valve Technology | September 24, 2018
Ancora Heart Inc. announced positive clinical data from the company’s recently expanded U.S. early feasibility study...
Medtronic Announces TAVR Study of Aortic Stenosis Patients With Bicuspid Valves
News | Heart Valve Technology | September 19, 2018
The U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) to initiate a new...
4C Medical's AltaValve First-in-Human Experience to be Presented at TCT 2018
News | Heart Valve Technology | September 17, 2018
September 17, 2018 — 4C Medical Technologies Inc.
Overlay Init